Contrasting Climb Bio (CLYM) & Its Competitors

Climb Bio (NASDAQ:CLYM) is one of 1,061 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it compare to its competitors? We will compare Climb Bio to related businesses based on the strength of its analyst recommendations, earnings, valuation, dividends, risk, profitability and institutional ownership.

Risk & Volatility

Climb Bio has a beta of -0.25, suggesting that its stock price is 125% less volatile than the S&P 500. Comparatively, Climb Bio’s competitors have a beta of 3.65, suggesting that their average stock price is 265% more volatile than the S&P 500.

Profitability

This table compares Climb Bio and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Climb Bio	N/A	-42.21%	-41.39%
Climb Bio Competitors	-3,590.11%	-276.96%	-39.10%

Valuation and Earnings

This table compares Climb Bio and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Climb Bio	N/A	-$35.12 million	-0.98
Climb Bio Competitors	$9.59 billion	$147.39 million	-5.65

Climb Bio’s competitors have higher revenue and earnings than Climb Bio. Climb Bio is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Institutional and Insider Ownership

69.8% of Climb Bio shares are held by institutional investors. Comparatively, 44.1% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 3.2% of Climb Bio shares are held by company insiders. Comparatively, 13.7% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Climb Bio and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Climb Bio	0	0	1	1	3.50
Climb Bio Competitors	7867	21333	48983	1246	2.55

Climb Bio currently has a consensus target price of $10.00, indicating a potential upside of 378.47%. As a group, “Pharmaceutical preparations” companies have a potential upside of 187.16%. Given Climb Bio’s stronger consensus rating and higher probable upside, research analysts plainly believe Climb Bio is more favorable than its competitors.

Summary

Climb Bio beats its competitors on 7 of the 13 factors compared.

Climb Bio Company Profile

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.